HCP, Inc. (HCP) Director R Kent Griffin, Jr. Acquires 21,100 Shares
HCP, Inc. (NYSE:HCP) Director R Kent Griffin, Jr. bought 21,100 shares of HCP stock in a transaction that occurred on Monday, May 14th. The shares were acquired at an average price of $23.80 per share, for a total transaction of $502,180.00. Following the completion of the transaction, the director now directly owns 30,575 shares of the company’s stock, valued at approximately $727,685. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
HCP stock opened at $23.37 on Wednesday. The stock has a market capitalization of $11.18 billion, a PE ratio of 11.98, a PEG ratio of 5.99 and a beta of 0.24. The company has a current ratio of 0.15, a quick ratio of 0.15 and a debt-to-equity ratio of 1.25. HCP, Inc. has a 12 month low of $23.30 and a 12 month high of $23.70.
HCP (NYSE:HCP) last released its quarterly earnings data on Thursday, May 3rd. The real estate investment trust reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.38). The firm had revenue of $479.20 million during the quarter, compared to analysts’ expectations of $452.86 million. HCP had a negative return on equity of 0.13% and a negative net margin of 0.41%. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.51 earnings per share. equities analysts forecast that HCP, Inc. will post 1.81 earnings per share for the current fiscal year.
Several research firms recently weighed in on HCP. ValuEngine downgraded HCP from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. BMO Capital Markets reiterated a “hold” rating and set a $25.00 target price on shares of HCP in a research report on Thursday, May 3rd. Wells Fargo reduced their target price on HCP from $31.00 to $27.00 and set a “market perform” rating on the stock in a research report on Tuesday, March 20th. Jefferies Group reiterated a “hold” rating and set a $26.00 target price on shares of HCP in a research report on Tuesday, February 13th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $27.00 target price (down from $29.00) on shares of HCP in a research report on Wednesday, February 14th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $27.15.
Large investors have recently made changes to their positions in the stock. Vestpro Financial Partners Inc. dba CPF Texas purchased a new stake in shares of HCP during the 4th quarter valued at about $103,000. Archford Capital Strategies LLC purchased a new stake in shares of HCP during the 1st quarter valued at about $167,000. Advisor Partners LLC purchased a new stake in shares of HCP during the 1st quarter valued at about $228,000. Ellington Management Group LLC purchased a new stake in shares of HCP during the 4th quarter valued at about $232,000. Finally, Bank of Hawaii purchased a new stake in shares of HCP during the 1st quarter valued at about $238,000. Institutional investors and hedge funds own 90.46% of the company’s stock.
HCP Company Profile
HCP, Inc is a fully integrated real estate investment trust (REIT) that invests primarily in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.
Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.